Literature DB >> 17009964

Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.

J M Lancaster1, H K Dressman, J P Clarke, R A Sayer, M A Martino, J M Cragun, A H Henriott, J Gray, R Sutphen, A Elahi, R S Whitaker, M West, J R Marks, J R Nevins, A Berchuck.   

Abstract

Although the transition from early- to advanced-stage ovarian cancer is a critical determinant of survival, little is known about the molecular underpinnings of ovarian metastasis. We hypothesize that microarray analysis of global gene expression patterns in primary ovarian cancer and metastatic omental implants can identify genes that underlie the metastatic process in epithelial ovarian cancer. We utilized Affymetrix U95Av2 microarrays to characterize the molecular alterations that underlie omental metastasis from 47 epithelial ovarian cancer samples collected from multiple sites in 20 patients undergoing primary surgical cytoreduction for advanced-stage (IIIC/IV) serous ovarian cancer. Fifty-six genes demonstrated differential expression between ovarian and omental samples (P < 0.01), and twenty of these 56 differentially expressed genes have previously been implicated in metastasis, cell motility, or cytoskeletal function. Ten of the 56 genes are involved in p53 gene pathways. A Bayesian statistical tree analysis was used to identify a 27-gene expression pattern that could accurately predict the site of tumor (ovary versus omentum). This predictive model was evaluated using an external data set. Nine of the 27 predictive genes have previously been shown to be involved in oncogenesis and/or metastasis, and 10/27 genes have been implicated in p53 pathways. Microarray findings were validated by real-time quantitative PCR. We conclude that gene expression patterns that distinguish omental metastasis from primary epithelial ovarian cancer can be identified and that many of the genes have functions that are biologically consistent with a role in oncogenesis, metastasis, and p53 gene networks.

Entities:  

Mesh:

Year:  2006        PMID: 17009964     DOI: 10.1111/j.1525-1438.2006.00660.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  29 in total

1.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

2.  Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (USP17) Gene Family, is a Potential Target for Epithelial-Mesenchymal Transition in High-Grade Serous Ovarian Cancer.

Authors:  Nuri Yildirim; Gizem Calibasi Kocal; Zerrin Isik; Bahadır Saatli; Ugur Saygili; Tugba Uysal; Cagnur Ulukus; Meral Koyuncuoglu; Hulya Ellidokuz; Yasemin Basbinar
Journal:  Reprod Sci       Date:  2018-09-09       Impact factor: 3.060

Review 3.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

4.  Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Authors:  Nicole Urban; Jason D Thorpe; Lindsay A Bergan; Robin M Forrest; Archana V Kampani; Nathalie Scholler; Kathy C O'Briant; Garnet L Anderson; Daniel W Cramer; Christine D Berg; Martin W McIntosh; Patricia Hartge; Charles W Drescher
Journal:  J Natl Cancer Inst       Date:  2011-09-14       Impact factor: 13.506

5.  Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.

Authors:  Miranda P Ween; Katja Hummitzsch; Raymond J Rodgers; Martin K Oehler; Carmela Ricciardelli
Journal:  Clin Exp Metastasis       Date:  2010-12-12       Impact factor: 5.150

6.  AXL is an essential factor and therapeutic target for metastatic ovarian cancer.

Authors:  Erinn B Rankin; Katherine C Fuh; Tiffany E Taylor; Adam J Krieg; Margaret Musser; Jenny Yuan; Kevin Wei; Calvin J Kuo; Teri A Longacre; Amato J Giaccia
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

7.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Survival prediction based on inherited gene variation analysis.

Authors:  Mine S Cicek; Matthew J Maurer; Ellen L Goode
Journal:  Methods Mol Biol       Date:  2013

9.  Inherited determinants of ovarian cancer survival.

Authors:  Ellen L Goode; Matthew J Maurer; Thomas A Sellers; Catherine M Phelan; Kimberly R Kalli; Brooke L Fridley; Robert A Vierkant; Sebastian M Armasu; Kristin L White; Gary L Keeney; William A Cliby; David N Rider; Linda E Kelemen; Monica B Jones; Prema P Peethambaram; Johnathan M Lancaster; Janet E Olson; Joellen M Schildkraut; Julie M Cunningham; Lynn C Hartmann
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

10.  Genes associated with bowel metastases in ovarian cancer.

Authors:  Andrea Mariani; Chen Wang; Ann L Oberg; Shaun M Riska; Michelle Torres; Joseph Kumka; Francesco Multinu; Gunisha Sagar; Debarshi Roy; Deok-Beom Jung; Qing Zhang; Tommaso Grassi; Daniel W Visscher; Vatsal P Patel; Ling Jin; Julie K Staub; William A Cliby; Saravut J Weroha; Kimberly R Kalli; Lynn C Hartmann; Scott H Kaufmann; Ellen L Goode; Viji Shridhar
Journal:  Gynecol Oncol       Date:  2019-06-14       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.